×
phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies.
Blagden S., Spiliopoulou P., Spiers L., Gnanaranjan C., Qi C., Woodcock VK., Moschandreas J., Tyrrell HEJ., Griffiths L., Butcher C., Ghazaly E., Evans TRJ.
DOI
10.1093/annonc/mdy279.429
Type
Conference paper
Publication Date
2018-10-01T00:00:00+00:00
Volume
29 Suppl 8